Hidradenitis
MONDO:0002260An inflammatory disease involving a pathogenic inflammatory response in the apocrine sweat gland.
Also known as: apocrine sweat gland, apocrine sweat gland inflammation, inflammation of apocrine sweat gland
135 clinical trials for this condition and its sub-types, 21 tagged with Hidradenitis itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Hidradenitis
-
Hidradenitis suppurativa 135 trials
1 sub-type
- Familial acne inversa 0 trials Sub-types →
Most studied deeper sub-types
-
HS patients who responded to drug get extended access in new study
Disease control Recruiting nowThis study offers continued treatment with povorcitinib for up to 600 adults with hidradenitis suppurativa who completed a prior trial and saw benefit. The main goal is to track side effects over time, with a secondary focus on reducing skin abscesses, nodules, and tunnels. Parti…
Phase 3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New hope for teens with painful skin condition: experimental drug povorcitinib under study
Disease control Recruiting nowThis study tests an oral drug called povorcitinib in 40 adolescents aged 12 to 17 with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition causing painful boils and tunnels. Over 54 weeks, researchers will check the drug's safety, how the body processes it,…
Phase 2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New pill for painful skin disease enters first human tests
Disease control Recruiting nowThis first-in-human trial tests an oral drug called SAR447971 (KT-485) in healthy volunteers and people with hidradenitis suppurativa (HS), a chronic skin condition causing painful lumps. The study has three parts: single and multiple doses in healthy people, and multiple doses i…
Phase 1 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New hope for painful skin condition: experimental drug LAD328 enters phase 2 trial
Symptom relief Recruiting nowThis study tests whether the experimental drug LAD328 can reduce symptoms of hidradenitis suppurativa, a chronic skin condition causing painful lumps. About 50 adults with moderate-to-severe disease will receive either LAD328 or a placebo. The main goal is to see if the drug lead…
Phase 2 • Sponsor: Almirall, S.A. • Aim: Symptom relief
Last updated Aug 19, 2026 00:00 UTC